NCT05775900View on ClinicalTrials.gov

Efficacy and Safety of Triweekly Cetuximab in Combination With Capecitabine as First-line Maintenance Treatment for KRAS/BRAF Wild-type Metastatic Colorectal Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 1, 2023

Primary Completion Date

July 31, 2025

Study Completion Date

August 26, 2025

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

Cetuximab

Cetuximab will be given triweekly at a dose from 400mg/m2 to 700mg/m2.

DRUG

Capecitabine

Capecitabine will be given 2 weeks on/1 week off (1000mg/m2 BID po.)

Trial Locations (1)

510655

The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER